CORE--FAMILY ASCERTAINMENT AND GENETIC TESTING

遗传易感性检测核心的核心作用是提供 BRCA1突变检测资源，用于开发和维护Duke 家族性乳腺癌数据库(FBCD)，并开发和维护DNA 杜克大学乳腺癌孢子库内的银行。这将为以下方面提供资源 杜克大学医学院的遗传流行病学和分子研究 中心。这一努力的总体目标是推进我们的基本和 乳腺癌BRCA1易感基因的临床研究 这一目标是通过提供关键人员组装乳房来实现的 癌症家族数据，收集血液样本进行分子分析，以及 对DNA进行测序，以确定BRCA1突变的存在。基因 药敏测试核心将直接与Winer博士和 里默的研究，并将提供资源，以识别亲属 家族性乳腺癌-卵巢癌家族。遗传易感性 测试核心还将为DR提供BRCA1测序功能。 Mark和Berchuck对细胞的分子生物学和功能的研究 BRCA1基因。将生成数据以促进Berry博士和 普罗斯尼茨在开发决策模型方面的努力。所有统计分析 将由生物统计和数据管理核心执行。这个 基因易感性检测核心不仅将为 各种与孢子相关的项目，但将是未来的跳板 家族性乳腺癌的遗传流行病学和分子生物学研究。我们 还将与Steven Narod博士合作，并参与 北美乳腺癌联合会的活动。

The central role of the Genetic Susceptibility Testing Core is to provide a resource for BRCA1 mutation testing, to develop and maintain the Duke Familial Breast Cancer Database (FBCD), and develop and maintain a DNA bank within the Duke Breast Cancer SPORE. This will provide a resource for genetic epidemiologic and molecular studies at Duke University Medical Center. The overall goal of this effort is to advance our basic and clinical understanding of the BRCA1 susceptibility gene for breast cancer. This goal is accomplished by providing key personnel to assemble breast cancer family data, to collect blood samples for molecular analyses, and to sequence DNA to determine the presence of BRCA1 mutations. The Genetic Susceptibility Testing Core will directly interface with Drs.Winer's and Rimer's study and will provide the resource to identify relatives from familial breast-ovarian cancer families. The Genetic Susceptibility Testing Core will also provide BRCA1 sequencing capabilities for Drs. Mark's and Berchuck's study of the molecular biology and function of the BRCA1 gene. Data will be generated to facilitate Drs. Berry's and Prosnitz's effort in developing decision models. All statistical analyses will be performed by the Biostatistics and Data Management Core. The Genetic Susceptibility Testing Core will not only provide a resource for the various SPORE-related projects but will be a spring-board for future genetic epidemiologic and molecular studies of familial breast cancer. We will also collaborate with Dr. Steven Narod and participate in the activities of the North American Breast Cancer Consortium.